[1] UPADHYAY R, HAMMERICH L, PENG P, et al. Lymphoma:immune evasion strategies [J]. Cancers (Basel), 2015, 7(2):736-762.
[2] GALLUZZI L, CHAN T A, KROEMER G, et al. The hallmarks of successful anticancer immunotherapy [J]. Sci Transl Med, 2018, 10(459):eaat7807. doi: 10.1126/scitranslmed.aat7807.
[3] SONG C, PHUENGKHAM H, KIM Y S, et al. Syringeable immunotherapeutic nanogel reshapes tumor microenvironment and prevents tumor metastasis and recurrence [J]. Nat Commun, 2019, 10(1):37-45.
[4] CHEN Q, XU L, LIANG C, et al. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy [J]. Nat Commun, 2016, 7:13193. doi: 10.1038/ncomms13193.
[5] LU J, LIU X, LIAO Y P, et al. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression [J]. Nat Commun, 2017, 8(1):1811. doi: 10.1038/s41467-017-01651-9.
[6] ONDA M, KOBAYASHI K, PASTAN I. Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity [J]. Proc Natl Acad Sci, 2019, 116(10):4575-4582.
[7] RUSSELL S J, BARBER G N. Oncolytic viruses as antigen-agnostic cancer vaccines [J]. Cancer Cell, 2018, 33(4):599-605.
[8] NAKAO S, ARAI Y, TASAKI M, et al. Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade [J]. Sci Transl Med, 2020, 12(526):eaax7992. doi: 10.1126/scitranslmed.aax7992.
[9] MULLINS S R, VASILAKOS J P, DESCHLER K, et al. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies [J]. J Immunother Cancer, 2019, 7(1):244-261.
[10] REILLEY M J, MORROW B, AGER C R, et al. TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma [J]. J Immunother Cancer, 2019, 7(1):323. doi: 10.1186/s40425-019-0811-x.
[11] WANG C, YE Y, HOCHU G M, et al. Enhanced cancer immunotherapy by microneedle patch-assisted delivery of anti-PD1 antibody [J]. Nano Lett, 2016, 16(4):2334-2340.
[12] KNORR D A, DAHAN R, RAVETCH J V. Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity [J]. Proc Natl Acad Sci, 2018, 115(43):11048-11053.
[13] JACKAMAN C, NELSON D J. Intratumoral interleukin-2/agonist CD40 antibody drives CD4+-independent resolution of treated-tumors and CD4+-dependent systemic and memory responses [J]. Cancer Immunol Immunother, 2012, 61(4):549-560.
[14] SUBBIAH V, MURTHY R, HONG D S, et al. Cytokines produced by dendritic cells administered intratumorally correlate with clinical outcome in patients with diverse cancers [J]. Clin Cancer Res, 2018, 24(16):3845-3856.
[15] PITUCH K C, MISKA J, KRENCIUTE G, et al. Adoptive transfer of IL13Ralpha2-specific chimeric antigen receptor T cells creates a pro-inflammatory environment in glioblast [J]. Mol Ther, 2018, 26(4):986-995.
[16] GALLUZZI L, BUQUE A, KEPP O, et al. Immunogenic cell death in cancer and infectious disease [J]. Nat Rev Immunol, 2017, 17(2):97-111.
[17] RODRIGUEZ-RUIZ M E, VANPOUILLE-BOX C, MELERO I, et al. Immunological mechanisms responsible for radiation-induced abscopal effect [J]. Trends Immunol, 2018, 39(8):644-655.
[18] LI H, YU J, WU Y, et al. In situ antitumor vaccination:Targeting the tumor microenvironment [J]. J Cell Physiol, 2020, 235(7-8):5490-5500.
[19] HAMMERICH L, BINDER A, BRODY J D. In situ vaccination:Cancer immunotherapy both personalized and off-the-shelf [J]. Mol Oncol, 2015, 9(10):1966-1981.
[20] POL J, VACCHELLI E, ARANDA F, et al. Trial Watch:Immunogenic cell death inducers for anticancer chemotherapy [J]. Oncoimmunology, 2015, 4(4):e1008866. doi: 10.1080/2162402X.2015.1008866.
[21] TAHA M S, CRESSWELL G M, PARK J, et al. Sustained delivery of carfilzomib by tannic acid-based nanocapsules helps develop antitumor immunity [J]. Nano Lett, 2019, 19(11):8333-8341.
[22] CHEN G, EMENS L A. Chemoimmunotherapy:reengineering tumor immunity [J]. Cancer Immunol Immunother, 2013, 62(2):203-216.
[23] SETH A, HEO M B, LIM Y T. Poly (gamma-glutamic acid) based combination of water-insoluble paclitaxel and TLR7 agonist for chemo-immunotherapy [J]. Biomaterials, 2014, 35(27):7992-8001.
[24] ZHANG L, JING D, WANG L, et al. Unique photochemo-immuno-nanoplatform against orthotopic xenograft oral cancer and metastatic syngeneic breast cancer [J]. Nano Lett, 2018, 18(11):7092-7103.
[25] SCHMID P, ADAMS S, RUGO H S, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer [J]. N Engl J Med, 2018, 379(22):2108-2121.
[26] SILVA C G, CAMPS M G, LI T M, et al. Effective chemoimmunotherapy by co-delivery of doxorubicin and immune adjuvants in biodegradable nanoparticles [J]. Theranostics, 2019, 9(22):6485-6500.
[27] SHEEN M R, FIERING S. In situ vaccination: harvesting low hanging fruit on the cancer immunotherapy tree [J]. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2019, 11(1):e1524. doi: 10.1002/wnan.1524.
[28] LEE K L, MURRAY A A, LE D H T, et al. Combination of plant virus nanoparticle-based in situ vaccination with chemotherapy potentiates antitumor response [J]. Nano Lett, 2017, 17(7):4019-4028.
[29] LYNN G M, LAGA R, JEWELL C M. Induction of anti-cancer T cell immunity by in situ vaccination using systemically administered nanomedicines [J]. Cancer Lett, 2019, 459:192-203.
[30] SONG W, SHEN L, WANG Y, et al. Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap [J]. Nat Commun, 2018, 9(1):2237. doi: 10.1038/s41467-018-04605-x.
[31] RUOSLAHTI E. Tumor penetrating peptides for improved drug delivery [J]. Adv Drug Deliv Rev, 2017, 110-111:3-12.
[32] OU W, JIANG L, THAPA R K, et al. Combination of NIR therapy and regulatory T cell modulation using layer-by-layer hybrid nanoparticles for effective cancer photoimmunotherapy [J]. Theranostics, 2018, 8(17):4574-4590.
[33] LU J, LIU X, LIAO Y P, et al. Breast cancer chemo-immunotherapy through liposomal delivery of an immunogenic cell death stimulus plus interference in the IDO-1 pathway [J]. ACS Nano, 2018, 12(11):11041-11061.
[34] WANG X, LI M, REN K, et al. On-demand autophagy cascade amplification nanoparticles precisely enhanced oxaliplatin-induced cancer immunotherapy [J]. Adv Mater, 2020, 32(32):e2002160. doi: 10.1002/adma.202002160.
[35] WILHELM S, TAVARES A J, DAI Q, et al. Analysis of nanoparticle delivery to tumours [J]. Nat Rev Mater, 2016, 1:1-12.
[36] MOHAMMADPOUR R, CHENEY D L, GRUNBERGER J W, et al. One-year chronic toxicity evaluation of single dose intravenously administered silica nanoparticles in mice and their Ex vivo human hemocompatibility [J]. J Controlled Release, 2020, 324:471-481.
[37] DANHIER F. To exploit the tumor microenvironment:Since the EPR effect fails in the clinic, what is the future of nanomedicine? [J]. J Controlled Release, 2016, 244(Pt A):108-121.
[38] SINDHWANI S, SYED A M, NGAI J, et al. The entry of nanoparticles into solid tumours [J]. Nat Mater, 2020, 19(5):566-575.
[39] LI M, YANG Y T, HE Q, et al. Recent advances of nanocarriers in tumor immunotherapy [J]. Acta Pharm Sin (药学学报), 2017, 52(12):1839-1848.
[40] YU W D, SUN G, LI J, et al. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy [J]. Cancer Lett, 2019, 452:66-70.
[41] GORBET M J, RANJAN A. Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors:Recent progress and challenges in treatment and tracking response to immunotherapy [J]. Pharmacol Ther, 2020, 207:107456. doi: 10.1016/j.pharmthera.2019.107456.
[42] GOTO T. Radiation as an in situ auto-vaccination:current perspectives and challenges [J]. Vaccines (Basel), 2019, 7(3):100. doi: 10.3390/vaccines7030100.
[43] YOKOUCHI H, YAMAZAKI K, CHAMOTO K, et al. Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer [J]. Cancer Sci, 2008, 99(2):361-367.
[44] MINN I, ROWE S P, POMPER M G. Enhancing CAR T-cell therapy through cellular imaging and radiotherapy [J]. Lancet Oncol, 2019, 20(8):e443-e451.
[45] MIN Y, ROCHE K C, TIAN S, et al. Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy [J]. Nat Nanotechnol, 2017, 12(9):877-882.
[46] PATEL R B, YE M, CARLSON P M, et al. Development of an in situ cancer vaccine via combinational radiation and bacterial-membrane-coated nanoparticles [J]. Adv Mater, 2019, 31(43):e1902626. doi: 10.1002/adma.201902626.
[47] BROWN J M, WILSON W R. Exploiting tumour hypoxia in cancer treatment [J]. Nat Rev Cancer, 2004, 4(6):437-447.
[48] CHEN Q, CHEN J, YANG Z, et al. Nanoparticle-enhanced radiotherapy to trigger robust cancer immunotherapy [J]. Adv Mater, 2019, 31(10):e1802228. doi: 10.1002/adma.201802228.
[49] CASTANO A P, MROZ P, HAMBLIN M R. Photodynamic therapy and anti-tumour immunity [J]. Nat Rev Cancer, 2006, 6(7):535-545.
[50] KHOT M I, ANDREW H, SVAVARSDOTTIR H S, et al. A Review on the scope of photothermal therapy-based nanomedicines in preclinical models of colorectal cancer [J]. Clin Colorectal Cancer, 2019, 18(2):e200-e209.
[51] CHEN P M, PAN W Y, WU C Y, et al. Modulation of tumor microenvironment using a TLR-7/8 agonist-loaded nanoparticle system that exerts low-temperature hyperthermia and immunotherapy for in situ cancer vaccination [J]. Biomaterials, 2020, 230:119629. doi: 10.1016/j.biomaterials.2019.119629.
[52] PENG J, XIAO Y, LI W, et al. Photosensitizer micelles together with IDO inhibitor enhance cancer photothermal therapy and immunotherapy [J]. Adv Sci, 2018, 5(5):1700891. doi: 10.1002/advs.201700891.
[53] ZHOU B, SONG J, WANG M, et al. BSA-bioinspired gold nanorods loaded with immunoadjuvant for the treatment of melanoma by combined photothermal therapy and immunotherapy [J]. Nanoscale, 2018, 10(46):21640-21647.
[54] WANG R, HE Z, CAI P, et al. Surface-functionalized modified copper sulfide nanoparticles enhance checkpoint blockade tumor immunotherapy by photothermal therapy and antigen capturing [J]. ACS Appl Mater Interfaces, 2019, 11(15):13964-13972.
[55] WANG T, WANG D, YU H, et al. A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors [J]. Nat Commun, 2018, 9(1):1532. doi: 10.1038/s41467-018-03915-4.
[56] HAN Y, CHEN Z, ZHAO H, et al. Oxygen-independent combined photothermal/photodynamic therapy delivered by tumor acidity-responsive polymeric micelles [J]. J Controlled Release, 2018, 284:15-25.
[57] NAM J, SON S, OCHYL L J, et al. Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer [J]. Nat Commun, 2018, 9(1):1074. doi: 10.1038/s41467-018-03473-9.
[58] KWIATKOWSKI S, KNAP B, PRZYSTUPSKI D, et al. Photodynamic therapy-mechanisms, photosensitizers and combinations [J]. Biomed Pharmacother, 2018, 106:1098-1107.
[59] ZHU Y, XUE J, CHEN W, et al. Albumin-biomineralized nanoparticles to synergize phototherapy and immunotherapy against melanoma [J]. J Controlled Release, 2020, 322:300-311.
[60] CHEN S X, MA M, XUE F, et al. Construction of microneedle-assisted co-delivery platform and its combining photodynamic/immunotherapy [J]. J Controlled Release, 2020, 324:218-227.
[61] FENG B, HOU B, XU Z, et al. Self-amplified drug delivery with light-inducible nanocargoes to enhance cancer immunotherapy [J]. Adv Mater, 2019, 31(40):e1902960. doi: 10.1002/adma.201902960.
[62] KIM J, CHO H R, JEON H, et al. Continuous O2-evolving MnFe₂O₄ nanoparticle-anchored mesoporous silica nanoparticles for efficient photodynamic therapy in hypoxic cancer [J]. J Am Chem Soc, 2017, 139(32):10992-10995.
[63] JAIN R K. Antiangiogenesis strategies revisited:from starving tumors to alleviating hypoxia [J]. Cancer Cell, 2014, 26(5):605-622.
[64] LUO Z, ZHENG M, ZHAO P, et al. Self-monitoring artificial red cells with sufficient oxygen supply for enhanced photodynamic therapy [J]. Sci Rep, 2016, 6:23393. doi: 10.1038/srep23393.
[65] ZHOU T J, XING L, FAN Y T, et al. Light triggered oxygen-affording engines for repeated hypoxia-resistant photodynamic therapy [J]. J Controlled Release, 2019, 307:44-54.
[66] AGOSTINIS P, BERG K, CENGEL K A, et al. Photodynamic therapy of cancer:an update [J]. CA Cancer J Clin, 2011, 61(4):250-281.
[67] WANG M, SONG J, ZHOU F, et al. NIR-triggered phototherapy and immunotherapy via an antigen-capturing nanoplatform for metastatic cancer treatment [J]. Adv Sci, 2019, 6(10):1802157. doi: 10.1002/advs.201802157.
[68] TWUMASI-BOATENG K, PETTIGREW J L, KWOK Y Y E, et al. Oncolytic viruses as engineering platforms for combination immunotherapy [J]. Nat Rev Cancer, 2018, 18(7):419-432.
[69] LAWLER S E, SPERANZA M C, CHO C F, et al. Oncolytic viruses in cancer treatment:A review [J]. JAMA Oncol, 2017, 3(6):841-849.
[70] REHMAN H, SILK A W, KANE M P, et al. Into the clinic:Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy [J]. J Immunother Cancer, 2016, 4:53. doi: 10.1186/s40425-016-0158-5.
[71] ENGELAND C E, GROSSARDT C, VEINALDE R, et al. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy [J]. Mol Ther, 2014, 22(11):1949-1959.
[72] TÄHTINEN S, GRÖNBERG-VÖHÄ-KOSKELA S, LUMEN D, et al. Adenovirus improves the efficacy of adoptive T-cell therapy by recruiting immune cells to and promoting their activity at the tumor [J]. Cancer Immunol Res, 2015, 3(8):915-925.
[73] YAKKALA C, CHIANG C L, KANDALAFT L, et al. Cryoablation and immunotherapy:an enthralling synergy to confront the tumors [J]. Front Immunol, 2019, 10:2283. doi: 10.3389/fimmu.2019.02283.
[74] ZHAO H, ZHAO B, LI L, et al. Biomimetic decoy inhibits tumor growth and lung metastasis by reversing the drawbacks of sonodynamic therapy [J]. Adv Healthc Mater, 2020, 9(1):e1901335. doi: 10.1002/adhm.201901335.
[75] TREMBLE L F, O′BRIEN M A, SODEN D M, et al. Electrochemotherapy with cisplatin increases survival and induces immunogenic responses in murine models of lung cancer and colorectal cancer [J]. Cancer Lett, 2019, 442:475-482.
[76] NEJMAN D, LIVYATAN I, FUKS G, et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria [J]. Science, 2020, 368(6494):937-980.